Emcure Pharmaceuticals : Penalty Orders ₹57.74 Crore

Emcure Pharmaceuticals Limited has informed stock exchanges (NSE: EMCURE / BSE: 544210) regarding regulatory orders received from the Income Tax Department. The disclosures, submitted pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, outline an aggregate penalty exceeding ₹57.73 crore spanning seven financial years. Key HighlightsTotal Financial Impact: Aggregate penalty imposed stands at ₹57,73,96,732. Applicable Assessment Period: Financial Years 2014-15 to 2020-21 (Assessment Years 2015-16 to 2021-22). Adjudicating Authority: Deputy Commissioner of Income Tax, Central Circle 2(1) – Pune. Dispute Timeline: Litigation originally initiated on December 27, 2023. Company Response: Emcure is evaluating legal remedies and intends to file an appeal before the Appellate Authority.